This segment focuses on the research and development of intracellular enzyme replacement therapies for rare genetic liver diseases. PhaseRx utilizes its proprietary Hybrid mRNA technology platform to synthesize missing enzymes within the cell, addressing deficiencies like ornithine transcarbamylase deficiency (PRX-OTC), argininosuccinate lyase deficiency (PRX-ASL), and argininosuccinate synthetase deficiency (PRX-ASS1). Research and development activities include preclinical studies, clinical trials, and product pipeline advancement. The company's approach offers a potential for improved patient outcomes by providing targeted therapies for life-threatening inherited conditions. Market positioning is centered on addressing unmet medical needs in the rare disease space, with a competitive advantage in its innovative mRNA technology. Future opportunities include expanding the pipeline to other rare genetic disorders and securing regulatory approvals for its lead product candidates. Regulatory and clinical aspects are crucial, with the company actively pursuing FDA approvals and clinical validation. Partnerships and collaborations are essential for clinical trial execution and commercialization.